Tolerogenic CNP-104 Treatment Regulates Th17 Cells Thereby Slowing PBC Progression and Liver Stiffness
Time: 8:00 am
day: Conference Day One
Details:
• Demonstrating efficacy across multiple immunological and clinical mechanisms
• Highlighting the potential of CNP-105 to be the first disease-modifying treatment for PBC
• Delving into the safety and tolerability data supporting ASIT clinical studies
